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Abstract
Background: Coronavirus disease 2019 (COVID-19) is a disease primarily affecting the respiratory 
tract, however due to the nature of the pathogenesis it is able to affect the whole body. So far, no causative 
treatment has been found and the main strategy when dealing with COVID-19 relies on widespread 
vaccination programs and symptomatic treatment. Vitamin D due to its ability to modulate the immu-
nological system has been proposed as a factor playing role in the organism response to the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, we decided to perform this me-
ta-analysis which aimed to establish a connection between vitamin D status and COVID-19 infection.
Methods: Study was designed as a systematic review and meta-analysis. PubMed, EMBASE, Web of 
Science, Cochrane Collaboration Databases and Scopus electronic databases were searched for relevant 
studies from database inception to May 10th, 2021. Mean differences (MDs) with their 95% confidence 
intervals (CI) were calculated. 
Results: Thirteen studies providing data for 14,485 participants met the inclusion criteria. Mean 
vitamin D levels in SARS-CoV-2 negative patients was 17.7 ± 6.9 ng/mL compared to SARS-CoV-2 
positive patients 14.1 ± 8.2 ng/mL (MD = 3.93; 95% CI 2.84–5.02; I2 = 99%; p < 0.001).
Conclusions: Low serum vitamin D levels are statistically significantly associated with the risk of 
COVID-19 infection. Supplementation of vitamin D especially in the deficiency risk groups is indicated. 
(Cardiol J 2021; 28, 5: 647–654)
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Since the outbreak of the new type of coro-
navirus disease called novel coronavirus disease 
2019 (COVID-19) in Wuhan China in 2019 [1, 2] 
medical systems all over the world have been under 
immense pressure, resulting in a rapid increase 
in the cost of care [3]. The virus infects the host 
via angiotensin converting enzyme 2 (ACE2) [4]. 
Due to the fact that ACE2 expression is the high-
est in the respiratory tract [5] it is the respiratory 
symptoms that are most prominent in COVID-19, 
however the ACE2 is expressed in the whole body 
which explains the multisymptomatic nature of 
the disease [6]. Due to rapidly spreading nature 
of the disease and its ability to disorganize the 
healthcare systems by the increased number of 
patients requiring intensive care the research was 
focused on finding a causative treatment. Several 
drugs have been proposed which include, but are 
not limited to: hydroxychloroquine [7, 8], janus 
kinase 2 inhibitor Fedratinib [9] or Remdesmivir 
[10]. None of which had been able to demonstrate 
utility in the treatment of COVID-19. Therefore, 
the efforts were focused on the development of 
the vaccines and so far, there are several drugs 
on the market that are able to relieve some of 
the tension placed on the healthcare system by 
COVID-19 [11, 12]. However, while vaccination 
programs are widespread and the number of vac-
cinated patients grows, the underlying risk factors 
for the severe course of COVID-19 are still being 
investigated. So far, several factors were estab-
lished i.e.: obesity [13], diabetes [14] and smoking 
[15]. The common denominator for all of these risk 
factors is the disturbed immunological response 
which may in fact be the underlying mechanism 
for the severe course of COVID-19. One of the 
most common and thoroughly examined causes of 
immunosuppression is vitamin D deficiency [16]. 
Vitamin D plays a key role the modulation of the 
immunological response in both  autoimmune and 
infectious diseases [17], via multiple patterns. 
Among many others it modulates the maturation 
of macrophages [18], regulates the T-lymphocyte 
stimulatory function of antigen-presenting cells 
[19] and regulates B-lymphocyte proliferation [18]. 
Therefore, it comes as no surprise that in the era of 
COVID-19, vitamin D became an object of interest 
for much research worldwide in terms of prevent-
ing the severe course of the disease. We decided 
to perform this meta-analysis in order to establish 
a possible link between the levels of vitamin D and 
COVID-19 infections.
Methods
This trial was prepared following the recom-
mendations of the Preferred Reporting Items for 
Systematic Review and Meta-Analysis (PRISMA) 
guidelines [19]. Before commencing the study, 
analyses methods as well as inclusion and exclu-
sion criteria to be used were agreed upon. Because 
of the nature of this systematic review and meta-
analysis, this study was exempt review by the 
institutional review board.
Literature search
A systematic review was carried out using 
PubMed, EMBASE, Web of Science, Cochrane 
Collaboration Databases and Scopus electronic da-
tabases. The most recent search was performed on 
May 10th, 2021. Titles and abstracts were screened 
by two authors independently (A.G. and W.G.). All 
retrieved articles were reviewed by two authors 
(J.S. and A.G.). Any disagreement was resolved 
through consensus or, if necessary, by discussion 
with a third author (L.S.). 
The search was performed using the follow-
ing terms: “25-hydroxyvitamin D” OR “25(OH)D” 
OR “vitamin D” AND “coronavirus” OR “SARS- 
-CoV-2” OR “COVID-19”. A manual search of 
references listed in reviews and reports was also 
performed. Only full articles in the English lan-
guage were considered. All references were saved 
in an EndNote (End Note, Inc, Philadelphia, PA) 
library used to identify duplicates.
Inclusion and exclusion criteria
Studies included in this meta-analysis met 
the following PICOS criteria: (1) PARTICIPANTS; 
patients > 18 years of age, (2) INTERVENTION; 
SARS-CoV-2 positive patients, (3) COMPARISON; 
SARS-CoV-2 negative patients, (4) OUTCOMES; de-
tailed information for vitamin D-3 levels, (5) STUDY 
DESIGN; randomized controlled trials, quasi-rand-
omized or observational studies comparing cardiac 
arrest during and before the COVID-19 period for 
their effects in patients with cardiac arrest. Reviews, 
simulation trials, animal studies, letters, conference 
papers and case studies were excluded.
Data extraction
Two reviewers (L.S. and W.G.) independently 
assessed each article to determine which article 
met the inclusion criteria. Any disagreements 
were resolved by consensus with a third reviewer 
(A.G.). The following information was extracted 
from each included study: the first author’s name, 
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year of publication, study design, country, sample 
size, age, gender, vitamin D level in SARS-CoV-2 
positive and negative patients. 
Quality assessment
Two reviewers (A.G. and H.K.) independently 
extracted individual study data and evaluated 
studies for risk of bias. Any disagreements were 
discussed and resolved in a consensus meeting 
with the third reviewer (M.M.). The revised tool for 
risk of bias in randomized trials — RoB 2 tool was 
used to assess the quality of randomized studies 
[20]. Moreover, the Robvis application was used to 
visualize risk of bias assessments [21]. 
The evaluation consisted of the following 
domains: confounding, participant selection, clas-
sification of interventions, deviation from interven-
tions, missing data, outcome measurement and 
selection of reported results. Each domain was 
assessed according to the following scale: serious, 
moderate and low. 
Statistical analysis
All statistical analysis were performed using 
RevMan v.5.4 (The Cochrane Collaboration, Ox-
ford, Copenhagen, Denmark) and STATA v.16.1. 
(StataCorp LLC, Texas, USA). All tests were 2-sid-
ed and a p value of less than 0.05 was considered 
as statistically significant. To analyze dichotomous 
outcomes the Mantel-Haenszel method was used, 
and results are reported as odds ratios with a 95% 
confidence interval (CI) and two tailed p values. 
The inverse variance model with a 95% CI was 
used to analyze continuous outcome differences 
and data are reported as the mean difference (MD). 
Results are presented as risk ratios with 95% CI 
for dichotomous measures. When the continuous 
data were reported in the articles as the median and 
interquartile range, estimated means and standard 
deviations were calculated using the formula de-
scribed by Hozo et al. [22]. 
Data heterogeneity was assessed using the 
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Figure 1. Flow diagram showing stages of the database search and study selection as per Preferred Reporting Items 
for Systematic reviews and Meta-analysis (PRISMA) guideline.
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was detected with the chi-squared test with n – 1 
degrees of freedom, which was expressed as I2 [23]. 
For all analysis a random model was used. 
Results
Characteristics of studies included in the 
meta-analysis
A detailed description of the process of study 
selection was presented in Figure 1. We found 
1,027 potential citations during the search of 
databases. 234 articles were excluded because 
they were duplicates, and 722 articles were also 
excluded because they were unrelated studies. 
The remaining 71 articles were fully reviewed, and 
13 studies providing data for 14,485 participants 
met the inclusion criteria and were included in 
the current meta-analysis [24–36]. The details 
of selected trials are summarized in Table 1. Of 
those trials, 3 studies were performed in United 
Kingdom, 2 studies in Iran, 2 in Saudi Arabia, 2 in 
Italy, and 1 in each of the following countries: Spain, 
Republic of Korea, Israel and China. 
Result of the meta-analysis
Polled analysis of all 13 studies reported 
vitamin D levels in the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) negative 
versus positive patients is shown in Figure 2. Mean 
vitamin D levels in SARS-CoV-2 negative patients 
was 17.7 ± 6.9 ng/mL compared to SARS-CoV-2 
positive patients 14.1 ± 8.2 ng/mL (MD = 3.93; 
95% CI 2.84–5.02; I2 = 99%; p < 0.001). 
The detailed risk of bias abuts the meth-
odological quality of the included studies that are 
elaborated and summarized in Figures 3 and 4. 
Discussion
The number of reports indicating the potential 
role of vitamin D deficiency in the COVID-19 in-
creases [37]. The potential role in the prevention of 
a severe course of COVID-19 was further strength-
ened by the identification of calcitriol (active form 
of vitamin D) as the regulator of renin-angiotensin 
system (RAS), of which an overactivation is associ-
ated with poor prognosis [38, 39]. Abdollahi et al. 
[24] found that patients who suffer from vitamin D 
deficiency are more vulnerable to COVID-19 in-
fection. However, he underlines that the patients 
suffering from COVID-19 were more likely to be 
overweight or obese, while obesity is an independ-
ent risk factor for a more severe course of the 
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Figure 2. Forest plot of vitamin D levels between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
negative versus positive patients. The center of each square represents the weighted odds ratios for individual tri-
als, and the corresponding horizontal line stands for a 95% confidence interval (CI). The diamonds represent pooled 
results; SD — standard deviation.
Study Risk of bias domains
D1 D2 D3 D4 D5 D6 D7 Overall
Abdollahi et al. 2020 X — + — ? + — —
Al-Daghiri et al. 2021 + X — + — — — —
Alguwaihes et al. 2021 + — + — — — — —
Baktash et al. 2020 + + X X — + X —
D’Avolio et al. 2020 X — — + ? — — —
Hernandez et al. 2020 + — — + — — + —
Im et al. 2020 — — + + — — — —
Livingston et al. 2021 + + — + + — — +
Mardani et al. 2020 — — + + ? — — —
Marzon et al. 2020 — + — + + — — —
Raisi-Estabragh et al. 2020 — — + + ? — — —
Sulli et al. 2021 + + — + ? + + +
Ye et al. 2020 + + + + ? — + +
Figure 3. A summary table of review authors’ judgements for each risk of bias item for each study. Domains: 
D1 — bias due to confouding; D2 — bias due to selection of participats; D3 — bias in classification of interventions; 
D4 — bias due to deviations from intended interventions; D5 — bias due to missing data; D6 — bias in measure-
ment of outcomes; D7 — bias in selection of the reported result. Judgement: X  Serious; —  Moderate; +  Low; 
?  No information. 
www.cardiologyjournal.org 651
Luiza Szarpak et al., Vitamin D levels and COVID-19
obese are also more likely to suffer from vitamin D 
deficiency [41]. Another group that suffers from the 
vitamin D deficiency are older patients [42] both 
due to the worse overall state of health and due to 
drugs, they take. The study by Baktash et al. [27] 
found that the patients who are older than 65 years 
and present with the COVID-19 symptoms are 
more likely to be vitamin D deficient, have elevated 
markers of cytokine release syndrome and have an 
increased risk of respiratory failure. However, no 
difference was found in terms of mortality between 
the patients who were deficient and those who had 
their vitamin D within normal ranges, indicating 
that in the older group the overall poor prognosis 
is associated with the general health status and 
presence of comorbidities. These findings are 
consistent with those achieved by D’Avolio et al. 
[28], who also found that vitamin D was lower in 
the patients positive for COVID-19, while indicat-
ing that the supplementation of vitamin D might 
be useful for prevention of infection. 
The strategy of vitamin D supplementation 
as indicated by Grant et al. [43] suggests the 
rapid increase of vitamin D serum levels through 
the high supplementation for a few weeks going 
as high as 10,000 IU/day in order to achieve the 
normal range. This strategy has been used for 
considearable time and has proven to be safe in 
delaying frailty [44]. In the study by Al-Daghri et al. 
[26] vitamin D deficiency was only observed in the 
group of older patients, those with type 2 diabetes 
and lower density lipoprotein levels. Interestingly 
the author, contrary to Grant et al. [43] supports 
the idea of rather moderate vitamin D loading 
in deficient patients, not exceeding 2000 iu/day, 
which is supported by Bergman [45]. Alguwaihes 
et al. [25] provides interesting data regarding 
vitamin D deficiency and the risk of COVID-19 
in a hospital setting. While he did not find any 
evidence suggesting that the risk of infection 
increases in deficient patients, they are, in fact, 
at higher risk of mortality, possibly through an 
unregulated inflammatory response and cytokine 
storm [46]. Contrary to these findings Hernandez 
et al. [29] found no difference in the severity of 
the disease when accounting for vitamin D defi-
ciency, however he did find a higher prevalence of 
deficiency among hospitalized COVID-19 patients. 
When analyzing the nutritional status of patients 
suffering from COVID-19, Im et al. [30] they found 
that patients suffering from COVID-19 presented 
a higher percentage of vitamin D deficiency when 
compared with a control group, additionally while 
not statistically significant 30 out of 38 patients who 
suffered from respiratory distress were deficient in 
vitamin D. What is worth noting is that the patients 
who required mechanical ventilation were deficient 
in at least one nutrient. Therefore, it is advised to 
monitor and react to the nutritional status of the 
COVID-19 patients [47]. Mardani et al. [32], in 
his study, analyzed an association in the level of 
vitamin D and the severity of COVID-19, along 
with levels of ACE2 and neutrophil to lymphocyte 
ratio (NLR). The NLR is a useful tool to assess 
systemic inflammation [48] also in acute lung 
injury and acute respiratory distress syndrome 
[49] which are common findings in the severe 
course of COVID-19. Having found lower levels 
of vitamin D in COVID-19 patients, the authors 
concluded that the deficiency may cause an im-
munological imbalance, overactivation of the RAS 
pathway and therefore a hyperinflammation state. 
Raisi-Estabragh et al. [34] in her study found that 
vitamin D deficiency was not an independent risk 
factor for black, Asian and minority ethnicities and 
that a cascade of factors play a role rather than a sin-
gle one that can be pinpointed. In a study by Ye et al. 
[36], he found that vitamin D deficiency increases 
risk of COVID-19 infection, while the supple-
mentation of it provides protective effects against 
Figure 4. A plot of the distribution of review authors’ judgements across studies for each risk of bias item.
0% 25%
Low risk Moderate risk Serious risk No information
50% 75% 100%
Bias due to confouding
Bias due to selection of participants 
Bias in classication of interventions
Bias due to deviations from intended interventions 
Bias due to missing data
Bias in measurement of outcomes 
Bias in selection of the reported result
Overall risk of bias
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a severe course of the disease. These findings are 
further reinforced by Sulli et al. [35] who found 
that vitamin D deficiency is associated with more 
severe lung involvement, longer disease duration, 
and risk of death in elderly COVID-19 patients. 
A study by Livingstone et al. [31] among vitamin D 
deficiency indicates that social deprivation plays 
role in COVID-19 infection. While studies for the 
general population showed that social distancing 
is beneficial for the reduction in COVID-19 inci-
dence rate [50], we must differentiate between 
social distancing and deprivation since the latter 
is a well-established risk factor for worsening of 
health outcomes [51]. Merzon et al. [33] identified 
vitamin D deficiency as an independent risk factor 
not only for COVID-19 infection, but also hospi-
talization, other risk factors included were being 
male and over the age of 50. 
All of the studies measured levels of vitamin D 
at the moment of acute COVID-19 infection, how-
ever as previous studies showed [52], acute respira-
tory infection does not alter the vitamin D levels, 
therefore a sample on admission is representative.
Conclusions
Low serum vitamin D levels are statisti-
cally and significantly associated with the risk of 
COVID-19 infection. Supplementation of vitamin D 
especially in deficiency, risk groups are indicated.
Acknowledgments
The study was supported by the ERC Research 
Net and by the Polish Society of Disaster Medicine.
Conflict of interest: None declared
References
1. Song F, Shi N, Shan F, et al. Emerging 2019 Novel Coronavi-
rus (2019-nCoV) Pneumonia. Radiology. 2020; 295(1): 210–217. 
Erratum in: Radiology. 2020 Dec;297(3):E346., doi: 10.1148/
radiol.2020200274, indexed in Pubmed: 32027573.
2. Dzieciatkowski T, Szarpak L, Filipiak KJ, et al. COVID-19 chal-
lenge for modern medicine. Cardiol J. 2020; 27(2): 175–183, doi: 
10.5603/CJ.a2020.0055, indexed in Pubmed: 32286679.
3. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and 
economic burden of hospitalized COVID-19 patients in 
the United States. J Med Econ. 2021; 24(1): 308–317, doi: 
10.1080/13696998.2021.1886109, indexed in Pubmed: 33555956.
4. Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution 
of ACE2 protein, the functional receptor for SARS coronavirus. 
A first step in understanding SARS pathogenesis. J Pathol. 2004; 
203(2): 631–637, doi: 10.1002/path.1570, indexed in Pubmed: 
15141377.
5. Sungnak W, Huang Ni, Bécavin C, et al. SARS-CoV-2 entry 
factors are highly expressed in nasal epithelial cells together 
with innate immune genes. Nat Med. 2020; 26(5): 681–687, doi: 
10.1038/s41591-020-0868-6, indexed in Pubmed: 32327758.
6. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic de-
rivative of chloroquine, is effective in inhibiting SARS-CoV-2 in-
fection in vitro. Cell Discovery. 2020; 6(1), doi: 10.1038/s41421-
020-0156-0.
7. Sahraei Z, Shabani M, Shokouhi S, et al. Aminoquinolines against 
coronavirus disease 2019 (COVID-19): chloroquine or hydroxy-
chloroquine. Int J Antimicrob Agents. 2020; 55(4): 105945, doi: 
10.1016/j.ijantimicag.2020.105945, indexed in Pubmed: 32194152.
8. Wu D, Yang XO. TH17 responses in cytokine storm of 
COVID-19: An emerging target of JAK2 inhibitor Fedratinib. 
J Microbiol Immunol Infect. 2020; 53(3): 368–370, doi: 10.1016/j.
jmii.2020.03.005, indexed in Pubmed: 32205092.
9. Szarpak Ł, Dzieciątkowski T, Jaguszewski MJ, et al. Is remde-
sivir important in clinical practice as a treatment of COVID-19? 
A study based on meta-analysis data. Pol Arch Intern Med. 2021; 
131(1): 96–97, doi: 10.20452/pamw.15686, indexed in Pubmed: 
33231938.
10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of 
the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 
383(27): 2603–2615, doi: 10.1056/NEJMoa2034577, indexed in 
Pubmed: 33301246.
11. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety 
of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 
384(5): 403–416, doi: 10.1056/NEJMoa2035389, indexed in Pub-
med: 33378609.
12. Ho JSY, Fernando DI, Chan MY, et al. Obesity in COVID-19: 
a systematic review and meta-analysis. Ann Acad Med Singap. 
2020; 49(12): 996–1008, indexed in Pubmed: 33463658.
13. Abdi A, Jalilian M, Sarbarzeh PA, et al. Diabetes and COVID-19: 
a systematic review on the current evidences. Diabetes Res Clin 
Pract. 2020; 166: 108347, doi: 10.1016/j.diabres.2020.108347, 
indexed in Pubmed: 32711003.
14. Hu L, Chen S, Fu Y, et al. Risk factors associated with clinical out-
comes in 323 coronavirus disease 2019 (COVID-19) hospitalized 
patients in Wuhan, China. Clin Infect Dis. 2020; 71(16): 2089–
2098, doi: 10.1093/cid/ciaa539, indexed in Pubmed: 32361738.
15. Palacios C, Gonzalez L. Is vitamin D deficiency a major global 
public health problem? J Steroid Biochem Mol Biol. 2014; 144 
Pt A: 138–145, doi: 10.1016/j.jsbmb.2013.11.003, indexed in Pub-
med: 24239505.
16. Wacker M, Holick MF. Vitamin D: effects on skeletal and ex-
traskeletal health and the need for supplementation. Nutrients. 
2013; 5(1): 111–148, doi: 10.3390/nu5010111, indexed in Pub-
med: 23306192.
17. Hewison M, Freeman L, Hughes SV, et al. Differential regulation 
of vitamin D receptor and its ligand in human monocyte-de-
rived dendritic cells. J Immunol. 2003; 170(11): 5382–5390, doi: 
10.4049/jimmunol.170.11.5382, indexed in Pubmed: 12759412.
18. Xu H, Soruri A, Gieseler RK, et al. 1,25-Dihydroxyvitamin D3 
exerts opposing effects to IL-4 on MHC class-II antigen expres-
sion, accessory activity, and phagocytosis of human monocytes. 
Scand J Immunol. 1993; 38(6): 535–540, doi: 10.1111/j.1365-
3083.1993.tb03237.x, indexed in Pubmed: 8256111.
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items 
for systematic reviews and meta-analyses: the PRISMA state-
ment. PLoS Medicine. 2009; 6(7): e1000097, doi: 10.1371/jour-
nal.pmed.1000097.
www.cardiologyjournal.org 653
Luiza Szarpak et al., Vitamin D levels and COVID-19
20. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for 
assessing risk of bias in non-randomised studies of interven-
tions. BMJ. 2016; 355: i4919, doi: 10.1136/bmj.i4919, indexed in 
Pubmed: 27733354.
21. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (rob-
vis): An R package and Shiny web app for visualizing risk-of-
bias assessments. Res Synth Methods. 2021; 12(1): 55–61, doi: 
10.1002/jrsm.1411, indexed in Pubmed: 32336025.
22. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and vari-
ance from the median, range, and the size of a sample. BMC Med 
Res Methodol. 2005; 5: 13, doi: 10.1186/1471-2288-5-13, indexed 
in Pubmed: 15840177.
23. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring incon-
sistency in meta-analyses. BMJ. 2003; 327(7414): 557–560, doi: 
10.1136/bmj.327.7414.557, indexed in Pubmed: 12958120.
24. Abdollahi A, Kamali Sarvestani H, Rafat Z, et al. The associa-
tion between the level of serum 25(OH) vitamin D, obesity, and 
underlying diseases with the risk of developing COVID-19 infec-
tion: A case-control study of hospitalized patients in Tehran, Iran. 
J Med Virol. 2021; 93(4): 2359–2364, doi: 10.1002/jmv.26726, 
indexed in Pubmed: 33314166.
25. Alguwaihes A, Sabico S, Hasanato R, et al. Severe vitamin D de-
ficiency is not related to SARS-CoV-2 infection but may increase 
mortality risk in hospitalized adults: a retrospective case–control 
study in an Arab Gulf country. Aging Clin Exp Res. 2021; 33(5): 
1415–1422, doi: 10.1007/s40520-021-01831-0.
26. Al-Daghri NM, Amer OE, Alotaibi NH, et al. Vitamin D status of 
Arab Gulf residents screened for SARS-CoV-2 and its associa-
tion with COVID-19 infection: a multi-centre case-control study. 
J Transl Med. 2021; 19(1): 166, doi: 10.1186/s12967-021-02838-x, 
indexed in Pubmed: 33902635.
27. Baktash V, Hosack T, Patel N, et al. Vitamin D status and 
outcomes for hospitalised older patients with COVID-19. 
Postgrad Med J. 2021; 97(1149): 442–447, doi: 10.1136/post-
gradmedj-2020-138712, indexed in Pubmed: 32855214.
28. D’Avolio A, Avataneo V, Manca A, et al. 25-Hydroxyvitamin D 
concentrations are lower in patients with positive PCR for SARS- 
-CoV-2. Nutrients. 2020; 12(5), doi: 10.3390/nu12051359, in-
dexed in Pubmed: 32397511.
29. Hernández JL, Nan D, Fernandez-Ayala M, et al. Vitamin D 
Status in Hospitalized Patients with SARS-CoV-2 Infection. 
J Clin Endocrinol Metab. 2021; 106(3): e1343–e1353, doi: 
10.1210/clinem/dgaa733, indexed in Pubmed: 33159440.
30. Im JH, Je YS, Baek J, et al. Nutritional status of patients with 
COVID-19. Int J Infect Dis. 2020; 100: 390–393, doi: 10.1016/j.
ijid.2020.08.018, indexed in Pubmed: 32795605.
31. Livingston M, Plant A, Dunmore S, et al. Detectable respira-
tory SARS-CoV-2 RNA is associated with low vitamin D levels 
and high social deprivation. Int J Clin Pract. 2021 [Epub ahead 
of print]: e14166, doi: 10.1111/ijcp.14166, indexed in Pubmed: 
33797849.
32. Mardani R, Alamdary A, Mousavi Nasab SD, et al. Association 
of vitamin D with the modulation of the disease severity in 
COVID-19. Virus Res. 2020; 289: 198148, doi: 10.1016/j.virus-
res.2020.198148, indexed in Pubmed: 32866536.
33. Merzon E, Tworowski D, Gorohovski A, et al. Low plasma 
25(OH) vitamin D level is associated with increased risk of 
COVID-19 infection: an Israeli population-based study. FEBS J. 
2020; 287(17): 3693–3702, doi: 10.1111/febs.15495, indexed in 
Pubmed: 32700398.
34. Raisi-Estabragh Z, McCracken C, Bethell MS, et al. Greater 
risk of severe COVID-19 in Black, Asian and Minority Ethnic 
populations is not explained by cardiometabolic, socioeconomic 
or behavioural factors, or by 25(OH)-vitamin D status: study of 
1326 cases from the UK Biobank. J Public Health (Oxf). 2020; 
42(3): 451–460, doi: 10.1093/pubmed/fdaa095, indexed in Pub-
med: 32556213.
35. Sulli A, Gotelli E, Casabella A, et al. Vitamin d and lung out-
comes in elderly COVID-19 patients. Nutrients. 2021; 13(3), doi: 
10.3390/nu13030717, indexed in Pubmed: 33668240.
36. Ye K, Tang F, Liao X, et al. Does serum vitamin D level af-
fect COVID-19 infection and its severity? A case-control 
study. J Am Coll Nutr. 2020 [Epub ahead of print]: 1–8, doi: 
10.1080/07315724.2020.1826005, indexed in Pubmed: 33048028.
37. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer 
outcome? Lancet Diabetes Endocrinol. 2020; 8(7): 570, doi: 
10.1016/S2213 -8587(20)30183-2.
38. Mok C, Ng Y, Ahidjo B, et al. Calcitriol, the active form of vi-
tamin D, is a promising candidate for COVID-19 prophylaxis. 
bioRxiv. 2020, doi: 10.1101/2020.06.21.162396.
39. Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to 
answer? Lancet Diabetes Endocrinol. 2020; 8(9): 735–736, doi: 
10.1016/S2213-8587(20)30268-0, indexed in Pubmed: 32758429.
40. Petrakis D, Margină D, Tsarouhas K, et al. Obesity: a risk fac-
tor for increased COVID19 prevalence, severity and lethal-
ity (review). Mol Med Rep. 2020; 22(1): 9–19, doi: 10.3892/
mmr.2020.11127, indexed in Pubmed: 32377709.
41. Vranić L, Mikolašević I, Milić S. Vitamin D deficiency: conse-
quence or cause of obesity? Medicina (Kaunas). 2019; 55(9), 
doi: 10.3390/medicina55090541, indexed in Pubmed: 31466220.
42. Kweder H, Eidi H. Vitamin D deficiency in elderly: Risk factors 
and drugs impact on vitamin D status. Avicenna J Med. 2018; 
8(4): 139–146, doi: 10.4103/ajm.AJM_20_18, indexed in Pubmed: 
30319955.
43. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vi-
tamin D supplementation could reduce risk of influenza and 
COVID-19 infections and deaths. Nutrients. 2020; 12(4), doi: 
10.3390/nu12040988, indexed in Pubmed: 32252338.
44. Bacon CJ, Gamble GD, Horne AM, et al. High-dose oral vitamin 
D3 supplementation in the elderly. Osteoporos Int. 2009; 20(8): 
1407–1415, doi: 10.1007/s00198-008-0814-9, indexed in Pub-
med: 19101755.
45. Bergman P. The link between vitamin D and COVID-19: distin-
guishing facts from fiction. J Intern Med. 2021; 289(1): 131–133, 
doi: 10.1111/joim.13158, indexed in Pubmed: 32652766.
46. Daneshkhah A, Agrawal V, Eshein A, et al. Evidence for pos-
sible association of vitamin D status with cytokine storm and 
unregulated inflammation in COVID-19 patients. Aging Clin Exp 
Res. 2020; 32(10): 2141–2158, doi: 10.1007/s40520-020-01677-y, 
indexed in Pubmed: 32876941.
47. Mehta S. Nutritional status and COVID-19: an opportunity for 
lasting change? Clin Med (Lond). 2020; 20(3): 270–273, doi: 
10.7861/clinmed.2020-0187, indexed in Pubmed: 32341077.
48. Martins EC, Silveira Ld, Viegas K, et al. Neutrophil-lympho-
cyte ratio in the early diagnosis of sepsis in an intensive care 
unit: a case-control study. Rev Bras Ter Intensiva. 2019; 31(1): 
64–70, doi: 10.5935/0103-507X.20190010, indexed in Pubmed: 
30916236.
49. Wang Y, Ju M, Chen C, et al. Neutrophil-to-lymphocyte ratio as 
a prognostic marker in acute respiratory distress syndrome pa-
tients: a retrospective study. J Thorac Dis. 2018; 10(1): 273–282, 
doi: 10.21037/jtd.2017.12.131, indexed in Pubmed: 29600057.
50. VoPham T, Weaver MD, Hart JE, et al. Effect of social distanc-
ing on COVID-19 incidence and mortality in the US. medRxiv. 
2020, doi: 10.1101/2020.06.10.20127589, indexed in Pubmed: 
32587998.
51. Charlton J, Rudisill C, Bhattarai N, et al. Impact of deprivation on 
occurrence, outcomes and health care costs of people with mul-
tiple morbidity. J Health Serv Res Policy. 2013; 18(4): 215–223, 
doi: 10.1177/1355819613493772, indexed in Pubmed: 23945679.
52. Haugen J, Chandyo RK, Ulak M, et al. 25-hydroxy-vitamin D con-
centration is not affected by severe or non-severe pneumonia, 
or inflammation, in young children. Nutrients. 2017; 9(1), doi: 
10.3390/nu9010052, indexed in Pubmed: 28106720.
654 www.cardiologyjournal.org
Cardiology Journal 2021, Vol. 28, No. 5
